[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Acar O, Akinci M, Uluocak N, Akbulut F, Kilicaslan I, Gokce O: Paratesticular metastasis of malignant melanoma: a case report. Kaohsiung J Med Sci; 2008 Jun;24(6):315-8
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paratesticular metastasis of malignant melanoma: a case report.
  • We report a case of multimetastatic malignant melanoma that was diagnosed after histopathologic examination of the excised paratesticular mass.
  • Our patient initially visited the neurosurgery clinic due to low back pain.
  • The histopathologic findings were consistent with malignant melanoma.
  • He was referred to the oncology department for adjuvant treatment.
  • The patient died during the third month of chemotherapy.
  • Our case was unique because the malignant melanoma was widely metastatic and involved primarily paratesticular tissues without any invasion of the testis and epididymis.
  • [MeSH-major] Genital Neoplasms, Male / pathology. Genital Neoplasms, Male / secondary. Melanoma / diagnosis. Melanoma / pathology. Scrotum / pathology
  • [MeSH-minor] Back Pain. Biopsy. Epididymis / pathology. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis. Testis / pathology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18635417.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


2. Chuang WY, Lin JN, Hung IJ, Hsueh C: Undifferentiated sarcoma of the liver. Chang Gung Med J; 2002 Jun;25(6):399-404
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is believed to be a primitive mesenchymal neoplasm, which usually behaves in a highly malignant fashion.
  • Recently, long-term disease-free survival has been achieved in cases which underwent aggressive multimodal treatment.
  • Postoperative chemotherapy was recommended, but was refused by the patient's family.
  • Chemotherapy was refused once again by the patient's family, and she was lost to follow-up for 5 months.
  • The patient was brought to the outpatient clinic again because of abdominal fullness and back pain.
  • She was admitted and received chemotherapy with vincristine, ifosfamide, and cisplatin.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12173670.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


3. Gérard J, Berdin B, Portier G, Godon A, Tessier-Marteau A, Geneviève F, Zandecki M: [Bone marrow necrosis in two patients with neoplastic disorders]. Ann Biol Clin (Paris); 2007 Nov-Dec;65(6):636-42
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Nécrose médullaire chez deux patients atteints de maladies cancéreuses.
  • Bone marrow necrosis is defined by extensive necrosis of the myeloid tissue and bone marrow stroma.
  • Diagnosis is done on characteristic cytological pattern of the bone marrow aspiration and/or biopsy.
  • The first patient, aged 75, has been hospitalized for fever, asthenia and lower back pain.
  • An haematological malignancy was suspected after observation of a few peripheral blood blast cells, but necrosis was found on the bone marrow aspiration and could not lead to further haematological diagnosis.
  • Within next days, the white blood cell count and the number of blasts increased, leading to the diagnosis of acute monoblastic leukaemia.
  • A chemotherapy was started but the patient died 20 days after admission.
  • The second patient, aged 28, has been hospitalized for severe bleeding a few days after the diagnosis of a metastatic gastric tumour.
  • According to literature, bone marrow necrosis is in most instances secondary to either an haematological malignancy (60%) or to a solid tumour (30%), but only at times observed with a non-malignant disorder.
  • Bone pain, fever, cytopenias and elevated serum lactic dehydrogenase and alkaline phosphatase are frequently reported, but are mostly non specific of the diagnosis in these malignant conditions.
  • Examination of the bone marrow leads to the diagnosis: cells are pycnotic, scarcely recognizable in a background of amorphous extracellular eosinophilic proteinaceous material, and histology shows disappearance of fat spaces with preservation of the bone tissue.
  • Tissue hypoxemia due to microcirculation failure may be the main mechanism leading to the necrosis, whatever the related disorder.
  • Supportive care together with specific therapy of the causal disease must be started promptly.
  • [MeSH-minor] Adult. Aged. Biopsy. Humans. Male. Necrosis. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Bone marrow necrosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18039608.001).
  • [ISSN] 0003-3898
  • [Journal-full-title] Annales de biologie clinique
  • [ISO-abbreviation] Ann. Biol. Clin. (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


Advertisement
4. Mori N, Sawada T, Satoh H, Kawaguchi M, Hara H, Matsushita K: A resected case of solitary pancreatic metastasis from adenocarcinoma of the lung. JOP; 2008;9(6):698-703
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Primary lung cancer frequently metastasizes to distant organs; however, the pancreas is a relatively infrequent site of metastasis.
  • Because most metastatic cases in the pancreas tend to be discovered in patients only after malignant disease has become widely disseminated, it is extremely rare that a metachronous metastatic lesion limited to the pancreas is discovered with postoperative imaging and is surgically resectable.
  • The interval between the surgical treatment of lung cancer and the metachronous pancreatic metastasis was 22 months; there has been no recurrence of disease during the 24 months of follow-up after a pylorus-preserving pancreaticoduodenectomy.
  • CONCLUSION: Surgical treatment should be considered in patients with pancreatic metastasis from other organs if the disease is localized in the pancreas or if metastasis in other organs is controlled with chemotherapy and/or radiotherapy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Lung Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Back Pain / etiology. Humans. Male. Middle Aged. Neoplasm Metastasis. Recurrence. Shoulder Pain / etiology. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18981550.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


5. Manduch M, Dexter DF, Ellis PM, Reid K, Isotalo PA: Extraskeletal Ewing's sarcoma/primitive neuroectodermal tumor of the posterior mediastinum with t(11;22)(q24;q12). Tumori; 2008 Nov-Dec;94(6):888-91
Genetic Alliance. consumer health - Ewing's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraskeletal Ewing's sarcoma/primitive neuroectodermal tumor of the posterior mediastinum with t(11;22)(q24;q12).
  • Ewing's sarcoma/primitive neuroectodermal tumor family of tumors is part of a rare group of malignant neoplasms with small round-cell morphology.
  • We describe a 24-year-old woman who presented with non-specific back pain.
  • The patient underwent a left posterolateral thoracotomy and a T3-5 laminectomy with subsequent multi-agent chemotherapy.
  • Histopathologic examination of the tumor demonstrated sheets of primitive small round malignant cells that showed no visible differentiation.
  • The neoplasm was diagnosed as a Ewing's sarcoma/primitive neuroectodermal tumor, and cytogenetic studies confirmed a t(11;22)(q24;q12) chromosomal translocation and an associated trisomy of chromosome 2, supporting the histologic diagnosis.
  • Although rare, they need to be considered in the differential diagnosis of primary mediastinal tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19267114.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


6. Ahmed N, Laverick L, Sammons J, Zhang H, Maslin DJ, Hassan HT: Ajoene, a garlic-derived natural compound, enhances chemotherapy-induced apoptosis in human myeloid leukaemia CD34-positive resistant cells. Anticancer Res; 2001 Sep-Oct;21(5):3519-23
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ajoene, a garlic-derived natural compound, enhances chemotherapy-induced apoptosis in human myeloid leukaemia CD34-positive resistant cells.
  • The reputation of garlic as an effective remedy for tumours extends back to the Egyptian Codex Ebers of 1550 BC.
  • Several garlic compounds, including allicin and its corresponding sulfide, inhibit the proliferation of several human malignant cells.
  • Acute myeloid leukaemia (AML) is a heterogeneous malignant disease in which disease progression at the level of CD34-positive cells has a major impact on resistance to chemotherapy and relapse.
  • MATERIALS AND METHODS: The aim of the present study was to investigate the effect of ajoene on changes in the expression of apoptosis-related proteins: bcl-2 and caspase-3, induced by two principal drugs used in treatment of AML, cytarabine and fludarabine, in KGI human myeloid leukaemia CD34-positive-resistant cells.
  • RESULTS: Quantitative ELISA measurement of bcl-2 (units per million cells) showed treatment of KG1-resistant leukaemia cells with 40 microM ajoene alone to significantly reduce the bcl-2-expression from 239.5 +/- 1.5 in control cultures to only 22.0 +/- 4.0 in ajoene-treated cultures.
  • Ajoene significantly enhanced the inhibitory effect of the two chemotherapeutic drugs, cytarabine and fludarabine, on bcl-2-expression in KGI cells.
  • Quantitative measurement of activated caspase-3 (pg per million cells) showed the two drugs, cytarabine and fludarabine, significantly increased the activated caspase-3 level in KGI myeloid leukaemia cells.
  • In conclusion, the present results suggest a potential role for the combination of ajoene with fludarabine-based chemotherapy in the treatment of refractory and/or relapsed AML patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacology. Apoptosis / drug effects. Disulfides / pharmacology. Leukemia, Myeloid / drug therapy. Plant Extracts / pharmacology
  • [MeSH-minor] Antigens, CD34 / biosynthesis. Caspase 3. Caspases / metabolism. Cytarabine / administration & dosage. Drug Resistance, Neoplasm. Drug Synergism. Garlic / chemistry. Humans. Proto-Oncogene Proteins c-bcl-2 / biosynthesis. Tumor Cells, Cultured. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11848518.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Disulfides; 0 / Plant Extracts; 0 / Proto-Oncogene Proteins c-bcl-2; 04079A1RDZ / Cytarabine; 99A0041VG8 / ajoene; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


7. Kyriazi MA, Stafyla VK, Chatzinikolaou I, Koureas A, Chatziioannou A, Kondi-Paphiti A, Arkadopoulos N, Smyrniotis V: Surgical challenges in the treatment of leiomyosarcoma of the inferior vena cava: analysis of two cases and brief review of the literature. Ann Vasc Surg; 2010 Aug;24(6):826.e13-7
Genetic Alliance. consumer health - Leiomyosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical challenges in the treatment of leiomyosarcoma of the inferior vena cava: analysis of two cases and brief review of the literature.
  • Optimal treatment should include complete resection of the malignant lesion with preservation of venous return.
  • She received adjuvant chemotherapy and is free of recurrence almost 3 years after surgery.
  • The second case is that of a 56-year-old woman presenting with back pain due to an 8-cm retroperitoneal mass in close proximity to the right renal vein.
  • She received adjuvant chemotherapy, but was referred to our hospital with local recurrence 6 months after the operation and is suffering from disseminated abdominal disease almost a year postsurgery.
  • CONCLUSION: Radical surgical en bloc resection is the mainstay of treatment for IVC leiomyosarcomas.
  • [MeSH-minor] Abdominal Pain / etiology. Back Pain / etiology. Chemotherapy, Adjuvant. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Recurrence, Local. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Annals of Vascular Surgery Inc. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20471215.001).
  • [ISSN] 1615-5947
  • [Journal-full-title] Annals of vascular surgery
  • [ISO-abbreviation] Ann Vasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


8. Hassan HT: Ajoene (natural garlic compound): a new anti-leukaemia agent for AML therapy. Leuk Res; 2004 Jul;28(7):667-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ajoene (natural garlic compound): a new anti-leukaemia agent for AML therapy.
  • The reputation of garlic (Allium sativum) as an effective remedy for tumours extends back to the Egyptian Codex Ebers of 1550 b.c.
  • Several garlic compounds including allicin and its corresponding sulfide inhibit the proliferation and induce apoptosis of several human non-leukaemia malignant cells including breast, bladder, colorectal, hepatic, prostate cancer, lymphoma and skin tumour cell lines.
  • More significantly, ajoene profoundly enhanced the apoptotic effect of the two chemotherapeutic drugs: cytarabine and fludarabine in human CD34-positive resistant myeloid leukaemia cells through enhancing their bcl-2 inhibitory and caspase-3 activation activities.
  • Since acute myeloid leukaemia (AML) is a heterogeneous malignant disease in which disease progression at the level of CD34-positive cells has a major impact on resistance to chemotherapy and relapse and the inability to undergo apoptosis is a crucial mechanism of multi-drug resistance in AML patients.
  • The recent findings of the potent enhancing activity of ajoene on chemotherapy-induced apoptosis in CD34-positive resistant human myeloid leukaemia cells suggest a novel promising role for the treatment of refractory and/or relapsed AML patients as well as elderly AML patients.
  • [MeSH-major] Disulfides / therapeutic use. Garlic. Leukemia, Myeloid / drug therapy. Plant Extracts / therapeutic use
  • [MeSH-minor] Acute Disease. Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm. Drug Synergism. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15158086.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Editorial; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Disulfides; 0 / Plant Extracts; 99A0041VG8 / ajoene
  • [Number-of-references] 66
  •  go-up   go-down


9. Shimizu J, Arano Y, Murata T, Ishikawa N, Yachi T, Nomura T, Minato H: A case of intrathoracic giant malignant peripheral nerve sheath tumor in neurofibromatosis type I (von Recklinghausen's disease). Ann Thorac Cardiovasc Surg; 2008 Feb;14(1):42-7
Genetic Alliance. consumer health - Malignant peripheral nerve sheath tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of intrathoracic giant malignant peripheral nerve sheath tumor in neurofibromatosis type I (von Recklinghausen's disease).
  • The patient was a 32-year-old woman with neurofibromatosis I (von Recklinghausen's disease), with chief complaints of shortness of breath and back pain.
  • It was histologically diagnosed as a malignant peripheral nerve sheath tumor.
  • Neither an optimal extent of resection needed for complete resection of this tumor nor an optimal regimen of chemotherapy, radiotherapy, or other therapy for the tumor has yet been established.
  • [MeSH-minor] Adult. Diagnosis, Differential. Fatal Outcome. Humans. Magnetic Resonance Imaging. Neoplasm Recurrence, Local. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Peripheral type neurofibromatosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18292741.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


10. Koschmieder S, Fauth F, Kriener S, Hoelzer D, Seipelt G: Effective treatment of simultaneous small cell lung cancer and B-cell lymphoma. Leuk Lymphoma; 2002 Mar;43(3):645-7
Genetic Alliance. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of simultaneous small cell lung cancer and B-cell lymphoma.
  • Malignant lymphomas have been reported previously to coincide with adenocarcinomas of the stomach and, rarely, the kidney, breast, colon, liver, or lung.
  • Here, we describe the first case to our knowledge of a malignant lymphoma and an extensive disease small cell cancer of the lung.
  • A 60-year-old male was admitted for severe back pain and was found to have multiple enlarged lymph nodes, hepatosplenomegaly, and bilateral pleural effusions.
  • Further staging revealed a dense infiltration of the bone marrow by both a small cell lung cancer and a malignant lymphoma.
  • Both tumors responded well to chemotherapy.
  • This unique case report demonstrates that the simultaneous occurrence of small cell lung cancers and malignant lymphomas is extremely rare and may effectively be treated with chemotherapy.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow / pathology. Humans. Liver / pathology. Male. Middle Aged. Neoplasm Invasiveness. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12002773.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


11. Inoue C, Kato S, Higuchi K, Inoue H: [A case of malignant pleural mesothelioma with elevation of G-CSF and CYFRA in the serum and pleural fluid]. Nihon Kokyuki Gakkai Zasshi; 2007 Mar;45(3):243-7
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of malignant pleural mesothelioma with elevation of G-CSF and CYFRA in the serum and pleural fluid].
  • A 68-year-old man complaining of hoarseness and back pain, with no history of exposure to asbestos, was referred to our hospital in June 2002.
  • A diagnosis of squamous cell lung cancer was made based on bronchial washing cytology.
  • Persistent high fever and WBC count elevation did not respond to antibiotics, and reduced only after chemotherapy.
  • The biopsy of the growing tumor in the right lateral abdominal wall revealed carcinoma with sarcomatous component or biphasic-type malignant pleural mesothelioma (MPM).
  • In spite of chemotherapy and radiation therapy for the abdominal wall tumor, the tumor rapidly progressed and the patient died three months after admission.
  • However, immunohistochemical staining and tissue HABP staining revealed biphasic type MPM.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Granulocyte Colony-Stimulating Factor / biosynthesis. Keratins / metabolism. Mesothelioma / metabolism. Pleural Effusion / metabolism. Pleural Neoplasms / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419436.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Keratin-19; 0 / antigen CYFRA21.1; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 68238-35-7 / Keratins
  •  go-up   go-down


12. Yomo S, Tada T, Hirayama S, Tachibana N, Otani M, Tanaka Y, Hongo K: A case report and review of the literature. J Neurooncol; 2007 Jan;81(2):209-16

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary diffuse leptomeningeal gliomatosis (PDLG) is a rare central nervous system neoplasm in which gliomatous tissue is diffusely identified in the subarachnoid space with no evidence of a primary intraparenchymal tumor.
  • A 52-year-old man presented low back pain followed by sudden unconsciousness and had also cognitive dysfunction and meningeal sign.
  • Examinations of cerebrospinal fluid (CSF) did not show malignant cells but increased protein and pleocytosis.
  • He died 3 months later because of disease progression despite both radiotherapy and chemotherapy.
  • Reviewing previous cases of PDLG instructs that this entity is rare, resembles meningitis in clinical pictures, usually occurs in a relatively younger population and has more progressive clinical course than the ordinary form of malignant gliomas.
  • [MeSH-minor] Fatal Outcome. Humans. Low Back Pain / diagnosis. Magnetic Resonance Imaging. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Neurol. 1997 Sep;25(145):1419-21 [9377304.001]
  • [Cites] Surg Neurol. 1998 Oct;50(4):356-62; discussion 362 [9817460.001]
  • [Cites] Clin Neuropathol. 1987 Jul-Aug;6(4):164-8 [3652562.001]
  • [Cites] Pathology. 1999 Feb;31(1):59-63 [10212927.001]
  • [Cites] Neurosurgery. 1986 Mar;18(3):363-6 [3703199.001]
  • [Cites] J Forensic Sci. 2001 Mar;46(2):392-5 [11305449.001]
  • [Cites] AJNR Am J Neuroradiol. 1995 May;16(5):1018-20 [7639122.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2001 Feb;70(2):256-8 [11160482.001]
  • [Cites] Arch Pathol Lab Med. 2000 May;124(5):759-61 [10782164.001]
  • [Cites] J Neurosurg. 1992 Aug;77(2):302-6 [1625019.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2001 Jan;70(1):120-2 [11118261.001]
  • [Cites] Acta Neurochir (Wien). 1995;132(1-3):154-9 [7754854.001]
  • [Cites] Neurosurgery. 1995 Jan;36(1):166-8; discussion 169 [7708153.001]
  • [Cites] Acta Neurochir (Wien). 1990;102(3-4):145-8 [2336982.001]
  • [Cites] Neurol Sci. 2005 Jun;26(2):129-34 [15995830.001]
  • [Cites] Can J Neurol Sci. 1985 Aug;12 (3):278-81 [4052890.001]
  • [Cites] Am J Clin Oncol. 1999 Jun;22(3):243-6 [10362329.001]
  • [Cites] Pediatr Radiol. 1998 Aug;28(8):580-2 [9716625.001]
  • [Cites] Yonsei Med J. 2000 Aug;41(4):517-21 [10992815.001]
  • [Cites] J Neuropathol Exp Neurol. 1951 Jan;10(1):16-29 [14804124.001]
  • [Cites] Neurosurgery. 2003 Feb;52(2):324-29; discussion 330 [12535360.001]
  • [Cites] Acta Neuropathol. 2005 Sep;110(3):306-11 [16003541.001]
  • [Cites] J Neurooncol. 1998 Apr;37(2):161-7 [9524095.001]
  • [Cites] Childs Nerv Syst. 2003 Jun;19(5-6):298-304 [12761643.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(4):480-1 [8738401.001]
  • [Cites] Clin Neuropathol. 2000 May-Jun;19(3):126-30 [14606585.001]
  • [Cites] Clin Neurol Neurosurg. 2000 Dec;102(4):223-226 [11154809.001]
  • [Cites] J Comput Assist Tomogr. 1993 Mar-Apr;17(2):317-20 [8454762.001]
  • [Cites] J Neuroimaging. 1996 Oct;6(4):250-4 [8903081.001]
  • [Cites] J Neurooncol. 1993 Mar;15(3):275-83 [8360714.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2000 Sep;69(3):385-8 [10945815.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):261-4 [15980977.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):45-9 [8455062.001]
  • [Cites] Zentralbl Pathol. 1991;137(6):523-30 [1805932.001]
  • [Cites] Acta Neuropathol. 1990;80(3):338-41 [2399813.001]
  • [Cites] Rev Neurol (Paris). 1994;150(3):232-5 [7863170.001]
  • [Cites] Rev Neurol (Paris). 1994 Oct;150(10):700-3 [7792477.001]
  • [Cites] Eur J Radiol. 2001 Jan;37(1):5-7 [11274832.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1994 Apr;57(4):471-3 [8163998.001]
  • [Cites] J Neurosurg. 1986 Jun;64(6):968-73 [3701447.001]
  • [Cites] J Neurooncol. 2001 May;53(1):21-6 [11678426.001]
  • [Cites] Childs Nerv Syst. 2005 Jun;21(6):477-81 [15378329.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):724-8 [7674024.001]
  • [Cites] Childs Nerv Syst. 2003 Apr;19(4):197-203 [12682758.001]
  • [Cites] Br J Neurosurg. 2001 Feb;15(1):62-6 [11303666.001]
  • [Cites] J Neurosurg. 1985 Aug;63(2):283-7 [4020450.001]
  • (PMID = 17031563.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Li H, Hong W, Zhang R, Wu L, Liu L, Zhang W: Retrospective analysis of 67 consecutive cases of pure ovarian immature teratoma. Chin Med J (Engl); 2002 Oct;115(10):1496-500
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To investigate the development regularity, treatment methods and prognosis of ovary immature teratoma (POIT).
  • From the 1980s, this was followed by four-cycles of combination chemotherapy (VAC, PVB or BEP x 3 cycles) as post-operative adjuvant therapy.
  • Combined chemotherapy and multiple operations were performed for advanced and recurrent lesions.
  • The chief prognostic factors for this disease are clinical stage, pathological grade and adequate treatment.
  • It is characterized by the fact that recurrent tumors may be converted back to mature ones as time goes on.
  • With chemotherapy, these is a good opportunity to rescue those patients with recurrent tumors.
  • At present, treatment of POIT gives the most satisfactory results among all malignant ovarian germ cell tumor types.
  • Tests of serum specific tumor markers (CA19-9, AFP, CA125, CEA) performed preoperatively or before chemotherapy and during follow-up have been found helpful in the evaluation of prognosis.
  • [MeSH-minor] Adolescent. Adult. Biomarkers, Tumor / analysis. Child. Child, Preschool. Female. Humans. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12490095.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


14. Neville A, Hatem SF: Renal medullary carcinoma: unsuspected diagnosis at stone protocol CT. Emerg Radiol; 2007 Sep;14(4):245-7
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal medullary carcinoma: unsuspected diagnosis at stone protocol CT.
  • Renal medullary carcinoma (RMC) is an aggressive neoplasm occurring almost exclusively in adolescents and young adults with sickle cell (SC) hemoglobinopathies, usually sickle cell trait (SCT) or hemoglobin SC disease.
  • It is a highly malignant tumor, and responses to chemotherapy are rare and transient resulting in a dismal prognosis.
  • A high level of suspicion is necessary when evaluating at risk patients presenting with hematuria or flank pain, as currently it appears that only early diagnosis could potentially alter the outcome of this disease.
  • We report a case of RMC in a young male patient with SCT, who presented to the emergency department with low back pain and microscopic hematuria, clinically mimicking acute obstructing urolithiasis.
  • Our case emphasizes the need to consider alternate diagnoses when evaluating computed tomography scans for acute flank pain.
  • [MeSH-major] Carcinoma, Renal Cell / diagnostic imaging. Kidney Neoplasms / diagnostic imaging. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Back Pain / diagnostic imaging. Contrast Media. Diagnosis, Differential. Fatal Outcome. Humans. Kidney Calculi / diagnostic imaging. Male

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1995 Jan;19(1):1-11 [7528470.001]
  • [Cites] J Urol. 2000 Apr;163(4):1238 [10737506.001]
  • [Cites] Pediatrics. 1999 Feb;103(2):E22 [9925868.001]
  • [Cites] J Urol. 2005 Jun;173(6):1883-8 [15879768.001]
  • [Cites] Pediatr Blood Cancer. 2005 Apr;44(4):407-11 [15602719.001]
  • [Cites] Abdom Imaging. 2003 Mar-Apr;28(2):210-6 [12592467.001]
  • [Cites] AJR Am J Roentgenol. 2000 May;174(5):1391-6 [10789801.001]
  • [Cites] Eur J Radiol. 2000 Jul;35(1):1-7 [10930759.001]
  • [Cites] Clin Radiol. 2002 Jun;57(6):435-41 [12069457.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jul;185(1):268-72 [15972435.001]
  • [Cites] Radiology. 1995 Apr;195(1):83-5 [7892499.001]
  • [Cites] Radiographics. 2000 Jan-Feb;20(1):215-43 [10682782.001]
  • [Cites] Am J Clin Oncol. 2003 Oct;26(5):489-92 [14528077.001]
  • [Cites] Emerg Radiol. 2004 Jul;10 (6):327-33 [15278717.001]
  • [Cites] Urology. 2002 Dec;60(6):1083-9 [12475675.001]
  • (PMID = 17406914.001).
  • [ISSN] 1070-3004
  • [Journal-full-title] Emergency radiology
  • [ISO-abbreviation] Emerg Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


15. Strik H, Prömmel P: Diagnosis and individualized therapy of neoplastic meningitis. Expert Rev Anticancer Ther; 2010 Jul;10(7):1137-48
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and individualized therapy of neoplastic meningitis.
  • It occurs in approximately 5-10% of malignant diseases, most often in breast cancer, lung cancer, melanoma or B-cell lymphoma.
  • Symptoms of neoplastic meningitis are head or back pain, cranial nerve palsies, diffuse radicular symptoms or psychiatric disturbances.
  • Treatment must be individually shaped: the CSF dissemination may be treated with intrathecal chemotherapy with methotrexate or cytarabinoside (Ara-C).
  • Systemic chemotherapy is needed to control solid manifestations or, in the case of substances entering the CSF, to support intrathecal chemotherapy.
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / pharmacokinetics. Antineoplastic Agents / therapeutic use. Cerebrospinal Fluid / cytology. Combined Modality Therapy. Cranial Irradiation. Cytarabine / administration & dosage. Cytarabine / therapeutic use. Diagnostic Imaging. Female. Humans. Injections, Spinal. Liposomes. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Invasiveness. Nervous System Diseases / etiology

  • MedlinePlus Health Information. consumer health - Meningitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20645702.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Liposomes; 04079A1RDZ / Cytarabine
  •  go-up   go-down


16. Subbarayan PR, Sarkar M, Nelson G, Benitez E, Singhal S, Ardalan B: Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-FU resistance. Anticancer Res; 2010 Apr;30(4):1149-56
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Resistance to chemotherapy is a major issue in treating malignant diseases.
  • 5-Fluorouracil (5-FU) is the drug of choice in managing colorectal cancer (CRC) patients.
  • However, 5-FU resistance leads to eventual treatment failure.
  • Therefore, delaying or reversing the onset of 5-FU resistance will benefit these terminally ill patient populations.
  • We used TS-siRNA to reduce TS and resensitize HT29FU CRC cells back to this uracil analogue.
  • Using real-time polymerase chain reaction (PCR) and Western immunodetection assays, we analyzed the expression of TS and p53 mRNA and protein in control and experimental groups.
  • [MeSH-major] Colorectal Neoplasms / drug therapy. Fluorouracil / pharmacology. Pyrimidines / pharmacology. Thymidylate Synthase / biosynthesis. Tumor Suppressor Protein p53 / antagonists & inhibitors
  • [MeSH-minor] Drug Resistance, Neoplasm. Enzyme Induction / drug effects. HT29 Cells. Humans. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20530421.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Pyrimidines; 0 / RNA, Messenger; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 2.1.1.45 / Thymidylate Synthase; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Wadhwa RK, Shaya MR, Nanda A: Spinal cord compression in a patient with a pain pump for failed back syndrome: a chalk-like precipitate mimicking a spinal cord neoplasm: case report. Neurosurgery; 2006 Feb;58(2):E387; discussion E387
Hazardous Substances Data Bank. CALCIUM CARBONATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spinal cord compression in a patient with a pain pump for failed back syndrome: a chalk-like precipitate mimicking a spinal cord neoplasm: case report.
  • OBJECTIVE AND IMPORTANCE: The use of intrathecal morphine has been effective with few complications for chronic intractable pain of both benign and malignant origins.
  • CLINICAL PRESENTATION: We report the case of a 67-year-old female patient with failed back syndrome who presented with sensory complaints and back pain.
  • [MeSH-minor] Aged. Back Pain / drug therapy. Back Pain / radiography. Bupivacaine / administration & dosage. Diagnosis, Differential. Female. Humans. Syndrome

  • Genetic Alliance. consumer health - Spinal cord neoplasm.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462469.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] H0G9379FGK / Calcium Carbonate; Y8335394RO / Bupivacaine
  •  go-up   go-down


18. Yang F, Jin C, Long J, Yu XJ, Xu J, Di Y, Li J, Fu de L, Ni QX: Solid pseudopapillary tumor of the pancreas: a case series of 26 consecutive patients. Am J Surg; 2009 Aug;198(2):210-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Clinicopathologic factors were compared between benign and malignant cases to determine what features of the tumor could suggest malignant potential.
  • Clinical symptoms were nonspecific and included upper abdominal pain or discomfort, abdominal distention, and back pain.
  • The neoplasm was localized in the pancreatic head/neck in 14 patients and in the body/tail in 12 patients.
  • All of the tumors-including 8 pancreaticoduodenectomies, 10 distal pancreatectomies, 6 local resections, 1 total pancreatectomy, and 1 central pancreatectomy-were resected successfully.
  • No patient received chemotherapy or radiotherapy after surgery.
  • One of the 2 patients with malignant SPT, in whom Ki-67 immunoreactivity was >25%, developed local recurrence with liver metastasis 4 months and died 6 months after surgery.
  • CONCLUSIONS: SPT is a rare neoplasm with low malignant potential.
  • Characteristic computed axial tomography and magnetic resonance imaging scans combined with age and sex profile should be sufficient for the decision to operate.
  • Patients with malignant SPT should have careful follow-up.
  • The high proliferative index assessed by immunohistochemical staining for Ki-67 may predict poor outcome of malignant SPT.
  • [MeSH-minor] Abdominal Pain / etiology. Adolescent. Adult. Back Pain / etiology. Diagnostic Imaging. Female. Humans. Length of Stay. Male. Middle Aged. Pancreatectomy. Pancreaticoduodenectomy. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19268906.001).
  • [ISSN] 1879-1883
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Elter T, Eichhorst BF, Wendtner CM: Use of alemtuzumab and rituximab consolidation in CLL: Pros and cons. Curr Hematol Malig Rep; 2009 Jan;4(1):43-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As new therapeutic approaches have improved responses and outcomes in the treatment of chronic lymphocytic leukemia (CLL), the scientific community focuses now on diagnostic procedures and definitions of response in CLL.
  • The success of these new therapeutic tools can be traced back to the eradication of detectable disease in a significant number of patients.
  • This article describes various methods of assessing minimal residual disease and presents data demonstrating that new therapeutic approaches can eliminate residual malignant cells at the highest levels of sensitivity currently available.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Antigens, CD19 / genetics. Antigens, CD5 / genetics. Clinical Trials as Topic. Flow Cytometry. Humans. Neoplasm, Residual. Rituximab

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2337-42 [16618945.001]
  • [Cites] Cancer. 2008 Mar 15;112(6):1288-95 [18189296.001]
  • [Cites] Cancer. 2003 Dec 15;98(12):2657-63 [14669286.001]
  • [Cites] Blood. 1992 Jul 1;80(1):29-36 [1377051.001]
  • [Cites] Cancer. 2008 Jan 1;112(1):119-28 [17999417.001]
  • [Cites] Blood. 2002 Aug 1;100(3):768-73 [12130484.001]
  • [Cites] N Engl J Med. 2000 Dec 14;343(24):1750-7 [11114313.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5616-23 [17984186.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2319-25 [11588025.001]
  • [Cites] Leuk Lymphoma. 1992 Jun;7(3):195-204 [1282428.001]
  • [Cites] Br J Haematol. 1997 Apr;97(1):113-8 [9136949.001]
  • [Cites] J Clin Oncol. 2003 May 1;21(9):1746-51 [12721250.001]
  • [Cites] Leukemia. 2004 Jun;18(6):1093-101 [15071604.001]
  • [Cites] Blood. 1996 Sep 15;88(6):2228-35 [8822943.001]
  • [Cites] Lancet. 1996 May 25;347(9013):1432-8 [8676625.001]
  • [Cites] Blood. 2001 Jul 1;98(1):29-35 [11418459.001]
  • [Cites] Br J Haematol. 2009 Jan;144(1):95-8 [19016732.001]
  • [Cites] Eur J Haematol. 1998 Sep;61(3):197-203 [9753416.001]
  • [Cites] Hematol Cell Ther. 1999 Feb;41(1):13-8 [10193641.001]
  • (PMID = 20425437.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antibodies, Neoplasm; 0 / Antigens, CD19; 0 / Antigens, CD5; 0 / Antineoplastic Agents; 3A189DH42V / alemtuzumab; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


20. von Bubnoff N, Peschel C, Duyster J: Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back. Leukemia; 2003 May;17(5):829-38
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.
  • Cancer research within the last decades elucidated signaling pathways and identified genes and proteins that lead or contribute to malignant transformation of a cell.
  • Discovery of the Bcr-Abl oncoprotein as the molecular abnormality causing chronic myeloid leukemia (CML) paved the way for the development of a targeted anticancer therapy.
  • The substantial activity of imatinib mesylate (STI571, Glivec) in CML and Philadelphia (Ph)-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) changed the therapeutic approach to Ph+ leukemia and rang the bell for a new era of anticancer treatment.
  • However, when the phenomenon of relapse occurred despite continued imatinib treatment, we had to learn the lesson that imatinib can select for a resistant disease clone.
  • If such a clone still depends on Bcr-Abl, it either carries a BCR-ABL point mutation that prevents binding of the drug or expresses the fusion protein at high levels.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Drug Resistance, Neoplasm. Fusion Proteins, bcr-abl / antagonists & inhibitors. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Piperazines / therapeutic use. Pyrimidines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12750693.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Number-of-references] 85
  •  go-up   go-down


21. Braumann C, Jacobi CA, Rogalla S, Menenakos C, Fuehrer K, Trefzer U, Hofmann M: The tumor suppressive reagent taurolidine inhibits growth of malignant melanoma--a mouse model. J Surg Res; 2007 Dec;143(2):372-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The tumor suppressive reagent taurolidine inhibits growth of malignant melanoma--a mouse model.
  • METHODS: After general anesthesia, a midline laparotomy was performed and 1.5 million malignant melanoma cells (B78-D14) were applied in the spleen and 1 million cells at the back (C57BL/6).
  • RESULTS: The i.p. therapy caused a dose-dependent inhibition of total tumor growth (P = 0.003) and i.p. tumor growth (P = < 0.001), whereas subcutaneous (s.c.) tumor growth was not affected (P = 0.132) compared with the i.p. control group.
  • The i.v. therapy reduced the total tumor growth (P = 0.013) and the s.c. tumor growth (P = 0.016), whereas the i.p. tumor load was not reduced (P = 0.122) compared with the control group.
  • Both i.p. and i.v. therapy with 3% TRD significantly decreased the total number of metastatic lesions.
  • CONCLUSIONS: The i.p. and i.v. therapies reduce total tumor weight and number of metastatic lesions of disseminated malignant melanoma in a dose-dependent fashion in mice.
  • Our encouraging findings should be further confirmed in clinical studies examining the influence of TRD in patients with disseminated malignant melanoma for whom prognosis still remains dismal.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Melanoma / drug therapy. Soft Tissue Neoplasms / drug therapy. Taurine / analogs & derivatives. Thiadiazines / pharmacology
  • [MeSH-minor] Animals. Body Weight. Dose-Response Relationship, Drug. Female. Injections, Intraperitoneal. Injections, Intravenous. Mice. Mice, Inbred C57BL. Neoplasm Transplantation. Subcutaneous Tissue / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Taurine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17612567.001).
  • [ISSN] 0022-4804
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Thiadiazines; 1EQV5MLY3D / Taurine; 8OBZ1M4V3V / taurolidine
  •  go-up   go-down


22. Ruhland B, Dittmer C, Thill M, Diedrich K, Fischer D: Metastasized hemangiopericytoma of the breast: a rare case. Arch Gynecol Obstet; 2009 Sep;280(3):491-4
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liposarcoma, leiomyosarcoma, rhabdomyosarcoma, as well as hemangiopericytoma, are part of the soft tissue sarcoma group.
  • We present the case of a woman, who received primary diagnosis of a malignant hemangiopericytoma of the left breast.
  • She underwent a mastectomy with an axillary lymph node sampling (stage pT3 pN0 cM0), as adjuvant therapy was not mandatory.
  • Eight months after diagnosis, the patient presented with lumbar back pain, gluteal pain and right accentuated adynamia in both legs because of a disseminated osseous metastasis.
  • Two months after initiation of chemotherapy the patient died.
  • Diagnostic criteria and treatment principles in the metastatic situation are presented in addition to the literature to give a review about this rare malignancy.
  • [MeSH-major] Bone Neoplasms / secondary. Breast Neoplasms / pathology. Hemangiopericytoma / secondary. Hemangiopericytoma / therapy
  • [MeSH-minor] Aged. Axilla. Fatal Outcome. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Mastectomy. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19169699.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Tsz-Kan T, Man-Kwong C, Shu Shang-Jen J, Ying-Lee L, Wai Man-Wah A, Hon-Shing F: Radiofrequency ablation of recurrent fibromatosis. J Vasc Interv Radiol; 2007 Jan;18(1 Pt 1):147-50
Genetic Alliance. consumer health - Fibromatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiofrequency (RF) ablation has received increasing attention as a promising technique for treating focal malignant disease and is a safe and effective technique for tumor control.
  • The authors report a case in which RF ablation was performed in a woman with recurrent fibromatosis of the lower back who refused further surgery.
  • [MeSH-major] Catheter Ablation. Fibroma / therapy. Neoplasm Recurrence, Local / therapy. Soft Tissue Neoplasms / therapy. Subcutaneous Tissue / pathology
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Back. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Middle Aged. Seroma / etiology. Wound Infection / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17296717.001).
  • [ISSN] 1051-0443
  • [Journal-full-title] Journal of vascular and interventional radiology : JVIR
  • [ISO-abbreviation] J Vasc Interv Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


24. Martin L, Marples B, Coffey M, Lawler M, Hollywood D, Marignol L: Recognition of O6MeG lesions by MGMT and mismatch repair proficiency may be a prerequisite for low-dose radiation hypersensitivity. Radiat Res; 2009 Oct;172(4):405-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Low-dose hyper-radiosensitivity (HRS) is the phenomenon whereby cells exposed to radiation doses of less than approximately 0.5 Gy exhibit increased cell killing relative to that predicted from back-extrapolating high-dose survival data using a linear-quadratic model.
  • MMR (MSH2, MSH6, MLH1, PMS1, PMS2) and MGMT protein expression signatures were determined in a panel of normal (PWR1E, RWPE1) and malignant (22RV1, DU145, PC3) prostate cell lines and correlated with clonogenic survival and cell cycle analysis.
  • [MeSH-minor] Cell Division / drug effects. Cell Division / radiation effects. Cell Line, Tumor. Cell Survival / drug effects. Cell Survival / radiation effects. Dacarbazine / analogs & derivatives. Dacarbazine / pharmacology. Drug Resistance, Neoplasm / radiation effects. Enzyme Activation / drug effects. G2 Phase / drug effects. G2 Phase / radiation effects. Humans. Phenotype

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19772461.001).
  • [ISSN] 0033-7587
  • [Journal-full-title] Radiation research
  • [ISO-abbreviation] Radiat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 19916-73-5 / O(6)-benzylguanine; 5Z93L87A1R / Guanine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 9B710FV2AE / O-(6)-methylguanine; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


25. Adamina M, Daetwiler S, Rosenthal R, Zajac P: Clinical applications of recombinant virus-based cancer immunotherapy. Expert Opin Biol Ther; 2005 Sep;5(9):1211-24
MedlinePlus Health Information. consumer health - Genes and Gene Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer immunotherapy looks back over one century of clinical applications.
  • In spite of major advances in the comprehension of oncogenesis and treatment of cancer, malignant tumours remain a leading cause of disability and death worldwide.
  • This paper will attempt to shed some light on the perspectives opened by advanced cancer immunotherapy protocols, review the drawbacks of this approach and the reasons why it is believed that recombinant virus-based cancer immunotherapy may be of relevance in the treatment of human malignancies.
  • [MeSH-major] Antigens, Neoplasm / immunology. Cancer Vaccines / therapeutic use. Genetic Therapy / trends. Immunotherapy / trends. Neoplasms / therapy
  • [MeSH-minor] Animals. Carcinoembryonic Antigen / genetics. Carcinoembryonic Antigen / immunology. Carcinoembryonic Antigen / metabolism. Carcinoma in Situ / immunology. Carcinoma in Situ / prevention & control. Drug Design. Genetic Vectors. Granulocyte-Macrophage Colony-Stimulating Factor / genetics. Granulocyte-Macrophage Colony-Stimulating Factor / immunology. Granulocyte-Macrophage Colony-Stimulating Factor / metabolism. Humans. Randomized Controlled Trials as Topic. Retroviridae / genetics. Vaccines, Synthetic / therapeutic use. Vaccinia virus / genetics

  • MedlinePlus Health Information. consumer health - Cancer Immunotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16120051.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / Carcinoembryonic Antigen; 0 / Vaccines, Synthetic; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  • [Number-of-references] 115
  •  go-up   go-down






Advertisement